




ATC codes: **L01DB01**

Indication	Malignant neoplasms of breast <span style="background-color: #00a651; color: white; padding: 2px 5px; border-radius: 3px;">ICD11 code: 2D2Z</span>
INN	Doxorubicin
Medicine type	Chemical agent
List type	Complementary
Formulations	Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection ; 50 mg in vial (hydrochloride) powder for injection ; 2 mg per mL in 5 mL vial (hydrochloride) ; 2 mg per mL in 25 mL vial (hydrochloride)
EML status history	First added in 2015 (TRS 994) Changed in 2023 (TRS 1049)
Sex	All
Age	Adolescents and adults
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 
Tags	<span style="background-color: #ff69b4; border-radius: 10px; padding: 5px 15px; display: inline-block;">Cancer</span>
Wikipedia	<a href="#">Doxorubicin</a> 
DrugBank	<a href="#">Doxorubicin</a> 

### Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional dose forms of doxorubicin (2 mg/mL (hydrochloride) in 5 mL, 25 mL vial) to the EML and EMLc.

[Expert Committee report](#) 

